126 related articles for article (PubMed ID: 9740696)
1. Relationship between peritoneal washing cytology through implantable port system (IPS-cytology) and second-look laparotomy in ovarian cancer patients with unmeasurable residual diseases.
Fujiwara K; Yamauchi H; Yoshida T; Suzuki S; Oda T; Kohno I
Gynecol Oncol; 1998 Aug; 70(2):231-5. PubMed ID: 9740696
[TBL] [Abstract][Full Text] [Related]
2. Peritoneal washing cytology at second-look laparotomy in cisplatin-treated ovarian cancer patients.
Kudo R; Takashina T; Ito E; Mizuuchi H; Sagae S; Moriwaka O; Tamagawa A
Acta Cytol; 1990; 34(4):545-8. PubMed ID: 2375223
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
Barlow JJ; Lele SB
Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
[TBL] [Abstract][Full Text] [Related]
4. [Prognosis in ovarian cancer as a function of the results of the second-look laparatomy].
Varette C; de Gramont A; Louvet C; Gonzalez-Canali G; Krulik M; Drolet Y; Pigné A; Marpeau L; Barrat J; Gallot D
J Gynecol Obstet Biol Reprod (Paris); 1989; 18(2):222-7. PubMed ID: 2723353
[TBL] [Abstract][Full Text] [Related]
5. Second-look laparotomy for ovarian cancer provides reliable prognostic information and improves survival.
Friedman RL; Eisenkop SM; Wang HJ
Gynecol Oncol; 1997 Oct; 67(1):88-94. PubMed ID: 9345362
[TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal cis-platinum as salvage therapy for refractory epithelial ovarian cancer.
Hacker NF; Berek JS; Pretorius RG; Zuckerman J; Eisenkop S; Lagasse LD
Obstet Gynecol; 1987 Nov; 70(5):759-64. PubMed ID: 3658287
[TBL] [Abstract][Full Text] [Related]
7. Peritoneal cytology as an indicator of disease in patients with residual ovarian carcinoma.
Rubin SC; Dulaney ED; Markman M; Hoskins WJ; Saigo PE; Lewis JL
Obstet Gynecol; 1988 Jun; 71(6 Pt 1):851-3. PubMed ID: 3285264
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy--a randomized phase II study by theSouthwest Oncology Group.
Muggia FM; Liu PY; Alberts DS; Wallace DL; O'Toole RV; Terada KY; Franklin EW; Herrer GW; Goldberg DA; Hannigan EV
Gynecol Oncol; 1996 Jun; 61(3):395-402. PubMed ID: 8641622
[TBL] [Abstract][Full Text] [Related]
9. Second-look operation in ovarian cancer.
Podratz KC; Kinney WK
Cancer; 1993 Feb; 71(4 Suppl):1551-8. PubMed ID: 8431893
[TBL] [Abstract][Full Text] [Related]
10. Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second-look laparotomy.
Tarraza HM; Boyce CR; Smith WG; Jones MA
Gynecol Oncol; 1993 Sep; 50(3):287-90. PubMed ID: 8406188
[TBL] [Abstract][Full Text] [Related]
11. [Second-look laparotomy in epithelial ovarian cancer: an evaluation of 23 cases].
Liu LY
Zhonghua Fu Chan Ke Za Zhi; 1990 Mar; 25(2):77-9, 123. PubMed ID: 2364794
[TBL] [Abstract][Full Text] [Related]
12. Systematic pelvic and paraaortic lymphadenectomy at second-look laparotomy for ovarian cancer.
Baiocchi G; Grosso G; di Re E; Fontanelli R; Raspagliesi F; di Re F
Gynecol Oncol; 1998 May; 69(2):151-6. PubMed ID: 9600823
[TBL] [Abstract][Full Text] [Related]
13. Peritoneal cytology of ovarian cancer patients receiving intraperitoneal therapy: quantitation of malignant cells and response.
Sagae S; Berek JS; Fu YS; Chang N; Dauplat J; Hacker NF
Obstet Gynecol; 1988 Nov; 72(5):782-8. PubMed ID: 3173930
[TBL] [Abstract][Full Text] [Related]
14. Clinical aspects of second-look laparotomy in ovarian cancer.
Rubinstein E; Knudsen JB
Ann Chir Gynaecol; 1986; 75(3):177-9. PubMed ID: 3740786
[TBL] [Abstract][Full Text] [Related]
15. Second-look surgery in the management of epithelial ovarian carcinoma.
Podratz KC; Cliby WA
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S128-33. PubMed ID: 7835796
[TBL] [Abstract][Full Text] [Related]
16. Experience with implanted subcutaneous ports for intraperitoneal chemotherapy in ovarian cancer.
Malmström H; Carstensen J; Simonsen E
Gynecol Oncol; 1994 Jul; 54(1):27-34. PubMed ID: 8020835
[TBL] [Abstract][Full Text] [Related]
17. Results of second-look laparotomy in patients with early-stage ovarian carcinoma.
Walton L; Ellenberg SS; Major F; Miller A; Park R; Young RC
Obstet Gynecol; 1987 Nov; 70(5):770-3. PubMed ID: 3658289
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of intraoperative peritoneal cytology and intraperitoneal chemotherapy using CDDP combined with MMC for gastric carcinomatous peritonitis].
Kitamura M; Arai K; Iwasaki Y
Gan To Kagaku Ryoho; 1995 Sep; 22(11):1523-6. PubMed ID: 7574749
[TBL] [Abstract][Full Text] [Related]
19. [Current treatment concepts in ovarian cancer].
Salzer H
Gynakol Rundsch; 1989; 29 Suppl 3():35-9. PubMed ID: 2696698
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of second-look laparotomy for patients with epithelial ovarian carcinoma.
Kamura T; Tsukamoto N; Saito T; Kaku T; Matsuyama T; Nakano H
Int J Gynaecol Obstet; 1990 Oct; 33(2):141-7. PubMed ID: 1976547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
